▲ +450.36% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Checkpoint Therapeutics in the last 3 months. The average price target is $17.67, with a high forecast of $20.00 and a low forecast of $16.00. The average price target represents a 450.36% upside from the last price of $3.21.
The current consensus among 3 investment analysts is to buy stock in Checkpoint Therapeutics. This Buy consensus rating has held steady for over two years.
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in Phase I clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and Cosibelimab, a programmed death ligand-1 (PD-L1), which is in Phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was founded in 2014 and is headquartered in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.